Mednax’s (MD) Buy Rating Reaffirmed at Mizuho
Mednax Inc. (NYSE:MD)‘s stock had its “buy” rating reaffirmed by Mizuho in a report issued on Tuesday. They presently have a $79.00 price objective on the stock. Mizuho’s target price would suggest a potential upside of 22.06% from the stock’s previous close.
MD has been the topic of a number of other research reports. Jefferies Group lowered their target price on Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, August 26th. Zacks Investment Research cut Mednax from a “buy” rating to a “hold” rating in a research report on Saturday, July 30th. JPMorgan Chase & Co. reduced their price target on Mednax from $85.00 to $80.00 and set an “overweight” rating for the company in a research report on Friday, July 29th. Finally, Citigroup Inc. reduced their price target on Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 17th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Mednax presently has a consensus rating of “Buy” and an average price target of $76.11.
Shares of Mednax (NYSE:MD) traded up 0.085% during midday trading on Tuesday, hitting $64.775. The stock had a trading volume of 80,023 shares. Mednax has a 12 month low of $61.40 and a 12 month high of $85.10. The stock’s 50-day moving average is $65.70 and its 200-day moving average is $68.22. The stock has a market cap of $5.97 billion, a PE ratio of 18.078 and a beta of 0.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/mednaxs-md-buy-rating-reaffirmed-at-mizuho.html
Mednax (NYSE:MD) last posted its earnings results on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by $0.04. Mednax had a net margin of 11.17% and a return on equity of 14.88%. The firm earned $772 million during the quarter, compared to the consensus estimate of $775.68 million. During the same period in the prior year, the company posted $0.90 EPS. The firm’s revenue was up 14.1% compared to the same quarter last year. Equities analysts anticipate that Mednax will post $4.14 EPS for the current year.
In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the transaction, the director now owns 12,755 shares in the company, valued at approximately $829,202.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. KAMES CAPITAL plc raised its stake in Mednax by 2.1% in the second quarter. KAMES CAPITAL plc now owns 958,973 shares of the company’s stock valued at $69,439,000 after buying an additional 19,335 shares during the last quarter. Mason Street Advisors LLC bought a new stake in Mednax during the second quarter valued at about $3,073,000. Aristotle Capital Boston LLC raised its stake in Mednax by 3.7% in the second quarter. Aristotle Capital Boston LLC now owns 114,379 shares of the company’s stock valued at $8,284,000 after buying an additional 4,062 shares during the last quarter. Sterling Capital Management LLC raised its stake in Mednax by 5.1% in the second quarter. Sterling Capital Management LLC now owns 1,089,590 shares of the company’s stock valued at $78,919,000 after buying an additional 52,939 shares during the last quarter. Finally, Calvert Investment Management Inc. raised its stake in Mednax by 8.5% in the second quarter. Calvert Investment Management Inc. now owns 5,650 shares of the company’s stock valued at $409,000 after buying an additional 444 shares during the last quarter. Institutional investors and hedge funds own 96.87% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.